Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (12): 1345-1357.doi: 10.19982/j.issn.1000-6621.20220309
• Original Articles • Previous Articles Next Articles
Li Pengchuan1,2, Liang Yan2, Zhang Linxi1, Wu Xueqiong2()
Received:
2022-08-15
Online:
2022-12-10
Published:
2022-12-02
Contact:
Wu Xueqiong
E-mail:xueqiongwu@139.com
Supported by:
CLC Number:
Li Pengchuan, Liang Yan, Zhang Linxi, Wu Xueqiong. Bioinformatic analysis of the structure and function of Mycobacterium tuberculosis epitope-tandem protein W541[J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1345-1357. doi: 10.19982/j.issn.1000-6621.20220309
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220309
序号 | 起始氨基酸位置 | 终止氨基酸位置 | 氨基酸序列 | 氨基酸长度 (aa) |
---|---|---|---|---|
1 | 4 | 16 | PGLPVEYLQVPSP | 13 |
2 | 34 | 42 | PALYLLDGL | 9 |
3 | 64 | 72 | SGLSVVMPV | 9 |
4 | 84 | 90 | QPACGKA | 7 |
5 | 116 | 126 | KPTGSAVVGLS | 11 |
6 | 130 | 147 | SSALTLAIYHPQQFVYAG | 18 |
7 | 150 | 155 | SGLLDP | 6 |
8 | 194 | 200 | LLNVGKL | 7 |
9 | 207 | 212 | VWVYCG | 6 |
10 | 226 | 232 | AKFLEGF | 7 |
11 | 311 | 323 | AAAVVLPGLVGLA | 13 |
12 | 334 | 347 | RPGLPVEYLQVPSP | 14 |
13 | 365 | 373 | PAVYLLDGL | 9 |
14 | 394 | 403 | QSGLSIVMPV | 10 |
15 | 415 | 421 | SPACGKA | 7 |
16 | 463 | 486 | AMILAAYHPQQFIYAGSLSALLDP | 24 |
17 | 527 | 532 | QIPKLV | 6 |
18 | 538 | 543 | LWVYCG | 6 |
19 | 621 | 627 | SRYLARV | 7 |
20 | 635 | 642 | GSGVLIPA | 8 |
21 | 648 | 654 | LLDVTAE | 7 |
22 | 676 | 682 | GIPFAAA | 7 |
23 | 684 | 698 | GTAVQDSRSHVYAHQ | 15 |
表型的分类 | SYFPEITHI 表位个数 (分数范围) | RANKPEP 表位个数 (分数范围) |
---|---|---|
HLA-DRB1*0101 | 173(18~33) | 14(10.309~17.684) |
HLA-DRB1*0301 | 43(18~38) | 3(18.663~31.908) |
HLA-DRB1*0401 | 98(18~28) | 14(12.033~17.406) |
HLA-DRB1*0701 | 64(18~32) | 9(12.996~23.048) |
HLA-DRB1*0801 | 无法预测 | 6(11.212~16.537) |
HLA-DRB1*1101 | 26(18~27) | 14(10.986~17.764) |
HLA-DRB1*1501 | 109(18~28) | 8(10.085~20.508) |
表型 | 氨基酸 起始位置 | SYFPEITHI 氨基酸序列 | 得分 | 氨基酸 起始位置 | RANKPEP 氨基酸序列 | 得分 |
---|---|---|---|---|---|---|
HLA-DRB1*0101 | 7 | PVEYLQVPSPSMGRD | 30 | 10 | VLQVPSPSM | 12.654 |
80 | SDWYQPACGKAGCQT | 19 | 83 | YQPACGKAG | 12.113 | |
122 | VVGLSMAASSALTLA | 23 | 127 | MAASSALTL | 12.117 | |
147 | GAMSGLLDPSQAMGP | 23 | 145 | YAGAMSGLL | 14.746 | |
235 | TSNIKFQDAYNAGGG | 32 | 238 | IKFQDAYNA | 13.311 | |
304 | RRLMIGTAAAVVLPG | 24 | 304 | RRLMIGTAA | 14.952 | |
309 | GTAAAVVLPGLVGLA | 20 | 308 | IGTAAAVVL | 10.309 | |
316 | LPGLVGLAGGAATAG | 33 | 319 | LVGLAGGAA | 11.564 | |
337 | LPVEYLQVPSPSMGR | 21 | 341 | YLQVPSPSM | 12.654 | |
471 | PQQFIYAGSLSALLD | 25 | 476 | YAGSLSALL | 14.436 | |
572 | QDAYNAAGGHNAVFN | 28 | 571 | FQDAYNAAG | 12.192 | |
603 | NAMKGDLQGPGPGLR | 26 | 602 | LNAMKGDLQ | 15.046 | |
672 | GPGPGIPFAAAAGTA | 19 | 677 | IPFAAAAGT | 10.870 | |
674 | GPGIPFAAAAGTAVQ | 19 | 679 | FAAAAGTAV | 17.684 | |
HLA-DRB1*0301 | 15 | SPSMGRDIKVQFQSG | 35 | 18 | MGRDIKVQF | 31.908 |
271 | LNAMKPDLQRALGAT | 38 | 274 | MKPDLQRAL | 18.663 | |
346 | SPSMGRDIKVQFQSG | 35 | 349 | MGRDIKVQF | 31.908 | |
HLA-DRB1*0401 | 142 | QFVYAGAMSGLLDPS | 28 | 143 | FVYAGAMSG | 16.991 |
146 | AGAMSGLLDPSQAMG | 20 | 145 | YAGAMSGLL | 13.217 | |
188 | WQRNDPLLNVGKLIA | 18 | 186 | PAWQRNDPL | 12.403 | |
263 | SWEYWGAQLNAMKPD | 22 | 266 | YWGAQLNAM | 15.783 | |
264 | WEYWGAQLNAMKPDL | 22 | 267 | WGAQLNAMK | 12.536 | |
305 | RLMIGTAAAVVLPGL | 20 | 310 | TAAAVVLPG | 17.060 | |
390 | EWYYQSGLSIVMPVG | 22 | 391 | WYYQSGLSI | 14.604 | |
471 | PQQFIYAGSLSALLD | 28 | 474 | FIYAGSLSA | 15.043 | |
473 | QFIYAGSLSALLDPS | 22 | 476 | YAGSLSALL | 12.033 | |
496 | GLAMGDAGGYKAADM | 20 | 504 | GYKAADMWG | 12.665 | |
572 | QDAYNAAGGHNAVFN | 22 | 575 | YNAAGGHNA | 12.402 | |
594 | SWEYWGAQLNAMKGD | 22 | 597 | YWGAQLNAM | 15.783 | |
595 | WEYWGAQLNAMKGDL | 22 | 598 | WGAQLNAMK | 12.536 | |
690 | SRSHVYAHQAQTRHP | 18 | 695 | YAHQAQTRH | 17.406 | |
HLA-DRB1*0701 | 57 | AFEWYDQSGLSVVMP | 18 | 60 | WYDQSGLSV | 13.132 |
79 | YSDWYQPAC | 15.868 | ||||
83 | YQPACGKAG | 21.877 | ||||
94 | TYKWETFLTSELPGW | 26 | 94 | TYKWETFLT | 12.996 | |
407 | SSFYSDWYSPACGKA | 18 | 410 | YSDWYSPAC | 23.048 | |
414 | YSPACGKAG | 20.301 | ||||
425 | TYKWETFLTSELPQW | 26 | 425 | TYKWETFLT | 12.996 | |
572 | QDAYNAAGGHNAVFN | 20 | 571 | FQDAYNAAG | 14.758 | |
646 | QNLLDVTAEPARGRK | 22 | 643 | RRPQNLLDV | 13.518 | |
表型 | 氨基酸 起始位置 | SYFPEITHI 氨基酸序列 | 得分 | 氨基酸 起始位置 | RANKPEP 氨基酸序列 | 得分 |
HLA-DRB1*0801 | 205 | TRVWVYCGN | 11.687 | |||
264 | WEYWGAQLN | 15.670 | ||||
无法预测 | 436 | LPQWLSANR | 16.537 | |||
536 | TRLWVYCGN | 11.212 | ||||
595 | WEYWGAQLN | 15.670 | ||||
692 | SHVYAHQAQ | 13.431 | ||||
HLA-DRB1*1101 | 119 | GSAVVGLSMAASSAL | 18 | 95 | YKWETFLTS | 15.631 |
105 | LPGWLQANRHVKPTG | 19 | 107 | GWLQANRHV | 14.071 | |
106 | PGWLQANRHVKPTGS | 21 | 108 | WLQANRHVK | 10.986 | |
160 | GPTLIGLAMGDAGGY | 18 | 165 | GLAMGDAGG | 11.757 | |
191 | NDPLLNVGKLIANNT | 27 | 173 | GYKASDMWG | 16.074 | |
207 | VWVYCGNGKPSDLGG | 18 | 201 | IANNTRVWV | 14.316 | |
272 | NAMKPDLQRALGATP | 21 | 260 | GTHSWEYWG | 12.318 | |
313 | AVVLPGLVGLAGGAA | 20 | 299 | GGSGGRRLM | 15.719 | |
436 | LPQWLSANRAVKPTG | 19 | 426 | YKWETFLTS | 15.631 | |
491 | GPSLIGLAMGDAGGY | 18 | 496 | GLAMGDAGG | 11.757 | |
504 | GYKAADMWG | 12.782 | ||||
522 | NDPTQQIPKLVANNT | 21 | 531 | LVANNTRLW | 12.181 | |
532 | VANNTRLWV | 17.764 | ||||
618 | QHASRYLARVEAGGP | 20 | 591 | GTHSWEYWG | 12.813 | |
HLA-DRB1*1501 | 140 | PQQFVYAGAMSGLLD | 22 | 138 | YHPQQFVY | 10.212 |
226 | AKFLEGFVRTSNIKF | 24 | 226 | AKFLEGFVR | 12.196 | |
250 | HNGVFDFPDSGTHSW | 24 | 253 | VFDFPDSGT | 11.383 | |
319 | LVGLAGGAATAGAFS | 18 | 320 | VGLAGGAAT | 10.085 | |
463 | AMILAAYHPQQFIYA | 24 | 463 | AMILAAYHP | 11.442 | |
470 | HPQQFIYAGSLSALL | 18 | 469 | YHPQQFIYA | 12.231 | |
557 | AEFLENFVRSSNLKF | 24 | 557 | AEFLENFVR | 14.516 | |
581 | HNAVFNFPPNGTHSW | 28 | 584 | VFNFPPNGT | 20.508 |
表型分类 | 氨基酸 起始位 | 氨基酸序列 | RANKPEP | SYFPEITHI (得分≥18) | NetMHC | IEDB (得分>0.5) |
---|---|---|---|---|---|---|
HLA-A2 | 10 | YLQVPSPSM | / | 20 | 1.40≤WB | 0.685026 |
136 | AIYHPQQFV | / | 22 | 2.00≤WB | 0.669353 | |
158 | AMGPTLIGL | 68 | 27 | 0.70≤WB | 0.748173 | |
199 | KLIANNTRV | 86 | 23 | 0.40≤SB | 0.761698 | |
314 | VVLPGLVGL | / | 28 | 1.30≤WB | 0.723346 | |
341 | YLQVPSPSM | / | 20 | 1.40≤WB | 0.685026 | |
474 | FIYAGSLSA | / | 19 | 0.17≤SB | 0.592681 | |
482 | ALLDPSQGM | / | 21 | 1.70≤WB | 0.763105 | |
489 | GMGPSLIGL | / | 26 | 0.80≤WB | 0.675624 | |
662 | TLSDVLNEM | 83 | 22 | 0.60≤WB | 0.799273 | |
HLA-A3 | 167 | AMGDAGGYK | 9.914 | 18 | 0.60≤WB | 0.506313 |
498 | AMGDAGGYK | 9.914 | 18 | 0.60≤WB | 0.506313 | |
HLA-B7 | 3 | RPGLPVEYL | / | 26 | 0.40≤SB | 0.850273 |
70 | MPVGGQSSF | 18.044 | 18 | 0.12≤SB | 0.910081 | |
160 | GPTLIGLAM | / | 20 | 0.08≤SB | 0.811608 | |
334 | RPGLPVEYL | / | 26 | 0.40≤SB | 0.850273 | |
401 | MPVGGQSSF | 18.044 | 18 | 0.12≤SB | 0.910081 | |
491 | GPSLIGLAM | / | 22 | 0.06≤SB | 0.893546 | |
631 | GPGPGSGVL | / | 23 | 0.15≤SB | 0.893886 | |
640 | IPARRPQNL | 18.587 | 22 | 0.25≤SB | 0.966787 |
[1] |
Li W, Deng G, Li M, et al. A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice. Mol Immunol, 2014, 62(1): 86-95. doi:10.1016/j.molimm.2014.06.007.
doi: 10.1016/j.molimm.2014.06.007 URL |
[2] |
李小平, 贾再兴, 梁艳, 等. 结核潜伏感染相关蛋白Rv3407结构和功能的生物信息学分析. 中国病原生物学杂志, 2020, 15(8): 881-886,896. doi:10.13350/j.cjpb.200804.
doi: 10.13350/j.cjpb.200804 |
[3] |
Liang Y, Zhao Y, Bai X, et al. Immunotherapeutic effects of Mycobacterium tuberculosis rv3407 DNA vaccine in mice. Autoimmunity, 2018, 51(8): 417-422. doi:10.1080/08916934.2018.1546291.
doi: 10.1080/08916934.2018.1546291 pmid: 30632804 |
[4] |
Black GF, Thiel BA, Ota MO, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol, 2009, 16(8): 1203-1212. doi:10.1128/CVI.00111-09.
doi: 10.1128/CVI.00111-09 URL |
[5] |
Liang Y, Zhang X, Bai X, et al. Immunogenicity and Therapeutic Effects of Latency-Associated Genes in a Mycobacterium Tuberculosis Reactivation Mouse Model. Hum Gene Ther Methods, 2019, 30(2): 60-69. doi:10.1089/hgtb.2018.211.
doi: 10.1089/hgtb.2018.211 pmid: 30727774 |
[6] |
吴姝, 伊正君, 付玉荣. 结核分枝杆菌Pst S1蛋白结构与功能的生物信息学分析. 中国病原生物学杂志, 2019, 14(7): 806-810,821. doi:10.13350/j.cjpb.190713.
doi: 10.13350/j.cjpb.190713 |
[7] |
de Souza GA, Leversen NA, Målen H, et al. Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway. J Proteomics, 2011, 75(2): 502-510. doi:10.1016/j.jprot.2011.08.016.
doi: 10.1016/j.jprot.2011.08.016 pmid: 21920479 |
[8] | 殷月兰, 谈卫军, 连凯, 等. 结核分枝杆菌Ag85复合物三维结构及抗原表位预测. 扬州大学学报(农业与生命科学版), 2013, 34(4): 1-5. |
[9] |
刘静, 吴芳, 张杰, 等. 结核分枝杆菌Rv1733c蛋白的生物信息学分析. 中国病原生物学杂志, 2021, 16(3): 274-281. doi:10.13350/j.cjpb.210307.
doi: 10.13350/j.cjpb.210307 |
[10] |
伊星昊, 张德峰, 付玉荣. 结核分枝杆菌panD蛋白功能预测及生物信息学分析. 中国病原生物学杂志, 2017, 12(6): 500-504. doi:10.13350/j.cjpb.170604.
doi: 10.13350/j.cjpb.170604 |
[11] | 李江英, 白雪娟, 梁艳, 等. 用DNAStar软件预测Rv1410c结核分枝杆菌蛋白抗原表位. 细胞与分子免疫学杂志, 2015, 31(4):474-477. |
[12] | 陈燕, 娄加陶, 吴传勇, 等. 结核杆菌抗原Ag85A HLA-A*0201限制性CD8+-+CTL表位的预测和鉴定. 山东医药, 2007, 47(31): 17-20. |
[13] |
Liang Y, Zhang J, Yang Y, et al. Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with Mycobacterium tuberculosis. Vaccine, 2017, 35(32): 3995-4001. doi:10.1016/j.vaccine.2017.05.083.
doi: S0264-410X(17)30751-X pmid: 28625522 |
[14] | 郑越. 结核分支杆菌Ag85A、Ag85B DNA疫苗的构建、免疫原性及其保护效力的研究. 北京: 中国人民解放军军事医学科学院, 2003. |
[15] | 范琴. 结核疫苗优势抗原ESAT6、CFP10的分子生物学基础及应用研究进展. 生物医学工程学杂志, 2012, 29(2): 392-396. |
[16] | 袁伟. 结核分枝杆菌Ag85B-Esat6-HspX融合基因DNA疫苗的实验研究. 北京: 北京协和医学院(中国医学科学院), 2011. |
[17] |
Nunes-Alves C, Booty MG, Carpenter SM, et al. Human and Murine Clonal CD8+ T Cell Expansions Arise during Tuberculosis Because of TCR Selection. PLoS Pathog, 2015, 11(5): e1004849. doi:10.1371/journal.ppat.1004849.
doi: 10.1371/journal.ppat.1004849 |
[18] | 吴雪琼, 吴长有. 结核病免疫学. 北京: 人民卫生出版社, 2016. |
[1] | National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879. |
[2] | Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910. |
[3] | Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916. |
[4] | Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926. |
[5] | Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959. |
[6] | Dong Xiaowei, Guo Huixin, Zhang Chenchen, Wang Jiawen, He Junlei, Li Guanhai, Li Jianwei, Wen Wenpei. Application value of two-step detection of Mycobacterium tuberculosis infection screening in schools [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 802-807. |
[7] | Li Yinhong, Liu Fanglin, Lu Zhenhui, Jiang Xin. Study on the mechanism of Oridonin against pathological damage of tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 849-854. |
[8] | XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645. |
[9] | LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653. |
[10] | DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you. Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679. |
[11] | JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726. |
[12] | HE Yi-jun, CAO Xue-fang, GAO Lei. Interpretation of the Procedure of tuberculin skin test-interferon-gamma release assay two-step testing [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 438-441. |
[13] | DAI Guang-ming, WANG fen, CAO Ting-ming, CHU Hong-qian, HUANG Hai-rong, SUN Zhao-gang. Study on efficiency of Mycobacterium tuberculosis detection by real-time quantitative PCR with different clinical sample types and the improvement by grinding specimen with glass beads [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 450-454. |
[14] | LI Yu-jie, YANG Yu-ting, YANG Guo-ping. Research progress of innate immunity and adaptive immune response in diabetic patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 512-516. |
[15] | SUN Qing, LIAO Xin-lei, WANG Chen-qian, JIANG Guang-lu, DONG Ling-ling, WANG Fen, ZHAO Li-ping, HUANG Hai-rong, WANG Gui-rong. Characterization of rifampin resistance determining region mutations in tuberculosis patients with GeneXpert MTB/RIF positive RNA polymerase β subunit gene mutation [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 349-353. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||